Where do Anti-TROP2 ADCs Factor into Advanced TNBC Care?
| Overview / Abstract: |
Dive into additional groundbreaking treatment approaches for triple-negative breast cancer (TNBC) in this tumor board, the second in a series focused on TNBC. This multidisciplinary tumor board discusses a patient with advanced TNBC and how novel anti-TROP2 antibody drug conjugates (ADCs) therapy may play a role. |
|
Expiration |
Aug 03, 2023 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Online |
|
Credits / Hours |
.50 AMA PRA Category 1 Credit(s)™ |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
Sarah Donahue, MPH, NP, AOCNP; Amir Momeni-Boroujeni, MD; Rita Nanda, MD |
|
Sponsors / Supporters / Grant Providers |
Supported by an independent educational grant from Gilead Sciences, Inc. |
|
Keywords / Search Terms |
ACHL CME, CE, Continuing Medical Education, CME/CE, Online Learning, Webcasts, Newsletter, University of Chicago Pritzker School of Medicine Center for Continuing Medical Education, University of Chicago, triple-negative breast cancer, TNBC, Trop2, antibody drug conjugate (ADC), oncologists, oncology, breast cancer, racial disparities, estrogen receptor, progesterone Free CE CME |
|